Legend Capital has put its weight behind Shanghai Cell Therapy’s $39.6m series C1 round, two years after leading a $26.6m series B.
China-based immunotherapy developer Shanghai Cell Therapy has raised RMB275m ($39.6m) in a series C1 round backed by Legend Capital, the VC firm formed by conglomerate Legend Holdings, China Money Network reported today.
The round was led by China Industrial Asset Management, the private equity subsidiary of financial services firm Industrial Bank with a $25.9m commitment.
Founded in 2000, Shanghai Cell Therapy offers cancer diagnosis and treatment services, and also provides related offerings such as cell cryopreservation, gene detection, cell related…
Thierry Heles
Thierry Heles is editor-at-large of Global University Venturing and Global Corporate Venturing, and host of the Beyond the Breakthrough podcast.
